-
Risks Remain For Alexion Even As Early Internal Investigation Results Seem Positive
Monday, December 12, 2016 - 12:18pm | 360Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) plunged more than 15 percent Monday morning and hit a new 52-week low of $109.80 after the company's board of directors announced CEO David Hallal will leave the company amid an ongoing audit and finance committee investigation. The company's...
-
Alexion Management Changes Overshadow Potentially Positive Audit Results
Monday, December 12, 2016 - 10:28am | 308Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) are down 13.6 percent in pre-market trading after the company dropped a bombshell that CEO David Hallal and board member Vikas Sinha are leaving the company amid an ongoing audit and finance committee investigation. The news of the departures seems to...